{"id":"NCT01624233","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Japanese Participants With Moderate-to-Severe Psoriasis","officialTitle":"A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2013-09","completion":"2017-09","firstPosted":"2012-06-20","resultsPosted":"2016-09-30","lastUpdate":"2019-09-10"},"enrollment":91,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"80 mg ixekizumab","otherNames":["LY2439821"]}],"arms":[{"label":"80 mg ixekizumab","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.","primaryOutcome":{"measure":"Percentage of Participants Achieving â‰¥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)","timeFrame":"Week (Wk) 12","effectByArm":[{"arm":"80 mg Ixekizumab (LY2439821)","deltaMin":98.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":17,"countries":["Japan"]},"refs":{"pmids":["32910360","25355284"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":91},"commonTop":["Viral upper respiratory tract infection","Eczema","Influenza","Arthralgia","Back pain"]}}